Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.11)
# 480
Out of 4,896 analysts
226
Total ratings
43.84%
Success rate
15.47%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Reiterates: Overweight | n/a | $3.68 | - | 6 | Mar 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $20.98 | +33.46% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $110.29 | +36.01% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $109.04 | +40.32% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $15.80 | -11.39% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $24.81 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $13.93 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $11.85 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $34.02 | +70.49% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $30.29 | +41.96% | 5 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $37.01 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.40 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $133.46 | +16.14% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.52 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $14.52 | +141.05% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.74 | +174.26% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.64 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.57 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.06 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.62 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $21.81 | +55.89% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $31.90 | +56.74% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.26 | -4.94% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.46 | +774.89% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.14 | +250.88% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $32.17 | +80.29% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $7.14 | +1,440.62% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $3.59 | +2,128.41% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.29 | +132.56% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $11.11 | -0.99% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $8.78 | +36.75% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $6.84 | +2,356.14% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.13 | +838.97% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $17.01 | +1,075.78% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.41 | +887.65% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.13 | +1,026.76% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.36 | +10,488.24% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.32 | +203.03% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $57.15 | -31.76% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $71.88 | -79.13% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $0.49 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $4.14 | +4,247.83% | 1 | Oct 9, 2017 |
COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.68
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $20.98
Upside: +33.46%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $110.29
Upside: +36.01%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $109.04
Upside: +40.32%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $15.80
Upside: -11.39%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $24.81
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.93
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.85
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $34.02
Upside: +70.49%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $30.29
Upside: +41.96%
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $37.01
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.40
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $133.46
Upside: +16.14%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.52
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $14.52
Upside: +141.05%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.74
Upside: +174.26%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.64
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.57
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.06
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.62
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $21.81
Upside: +55.89%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $31.90
Upside: +56.74%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.26
Upside: -4.94%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.46
Upside: +774.89%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.14
Upside: +250.88%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $32.17
Upside: +80.29%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $7.14
Upside: +1,440.62%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $3.59
Upside: +2,128.41%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.29
Upside: +132.56%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $11.11
Upside: -0.99%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $8.78
Upside: +36.75%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $6.84
Upside: +2,356.14%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.13
Upside: +838.97%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $17.01
Upside: +1,075.78%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.41
Upside: +887.65%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.13
Upside: +1,026.76%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.36
Upside: +10,488.24%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.32
Upside: +203.03%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $57.15
Upside: -31.76%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $71.88
Upside: -79.13%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $0.49
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $4.14
Upside: +4,247.83%